NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit on behalf of shareholders who purchased shares of Under Armour, Inc. (NYSE: UA, UAA) from August 3, 2016 through November 1, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Under Armour, Inc. investors under the federal securities laws.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 6, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
To express an interest in the class action, go http://pawarlawgroup.com/cases/under-armour-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Under Armour shifted sales from quarter to quarter to appear healthier, including to keep pace with their long-running year-over-year 20% net revenue growth; (2) the Company had been under investigation by and cooperating with the U.S. Department of Justice and U.S. Securities and Exchange Commission since at least July 2017; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff. Attorney advertising.
Pawar Law Group represents investors from around the world.
Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1410
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
- Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China - July 7, 2020
- Strongbridge Biopharma plc Announces Appointment of John H. Johnson toChief Executive Officer - July 7, 2020
- Primoris Services Corporation Appoints Two New Members to Its Board of Directors - July 7, 2020